Helsinki University Central Hospital
Helsinki, 00029, Finland
NCT Number: NCT00797589
The use of Tetraspan® as prime solution can reduce fluid extravasation after perfusion versus Ringer acetate. Plasma-adapted HES-solutions produce also less acidosis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Helsinki, 00029, Finland
Fifty patients scheduled for elective primary and single cardiac surgery include in this prospective study. Patients with preoperative coagulation disorders, or renal or hepatic failure, are excluded.
Before admission to the operation theatre, the patients allocate in random order to receive one of the following solutions during the extracorporeal circulation:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
20ml/kg as prime fluid
Time frame: 1 postoperative day
University of Helsinki
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00903604
Acute Kidney Injury, Aortic Root or Ascending Aortic Aneurysm Repair Surgery
Copenhagen, Denmark
View Trial DetailsNCT07249164
Cardiac Surgical Procedures, Confusion
Taichung, Taichung City, Taiwan
View Trial DetailsNCT03823521
Coronary Artery Bypass Surgery, Valve Surgery
Innsbruck, Austria
View Trial DetailsNCT01006863
Cardiovascular Diseases, Hypotension
Al Mansurah, DK, Egypt
View Trial Details